Pharmaceutical Firm Accelerates Activities in Ear Disorders Area Cupertino, California – PRNewswire — DURECT Corporation, a pioneer in drug therapy treatments employing continuous drug delivery technology, today announced that it has acquired substantially all of the assets of IntraEAR, Inc. of Denver, CO. Specific terms of the deal were not announced. IntraEAR, Inc. was established […]
DURECT Corporation Acquires IntraEAR, Inc. Read More »
San Diego, California – PRNewswire — Genetronics Biomedical Ltd. (Amex: GEB; Toronto) today announced it has elected Felix Theeuwes, D.Sc., as a new member of its Board of Directors. Dr. Theeuwes is Chairman and Chief Scientific Officer at DURECT Corporation, which was established in 1998 to focus on products based on ALZA Corporation’s (NYSE: AZA
PRNewswire — DURECT Corporation, a pioneer in drug therapy treatments employing subcutaneous delivery technology, today announced the closing of a $20 million private placement of preferred convertible stock. The Series B placement led by Brookside Capital, a Bain Capital Fund, is DURECT’s second round of funding. Additional investors include J.P. Morgan Investment Management, Collinson Howe
Pharmaceutical Firm Developing Therapies for Promising New Drug Delivery System Read More »
